Summary Precision oncology has expanded rapidly across the Asia–Pacific region, yet implementation remains heterogeneous because of differences in health-system organisation, reimbursement, molecular tumour board infrastructure, workforce capacity, and data integration. This structured narrative review with expert cons...
H. Bando, H. Okayama, Yoon Jung Chang et al.· The Lancet Regional Health -...· 1 citation
Background Aging is a major nonmodifiable risk factor for cancer, yet age-associated genomic instability, inflammatory activation, and tumor microenvironment interactions remain poorly characterized. Patients and methods The primary genomic cohort comprised 153 treatment-naïve patients with six cancer types, stratified...
S. Yajima, Y. Tsukada, Y. Sota et al.· Immuno-Oncology Technology· 0 citations
It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...
T. Hashimoto, T. Shibuki, T. Fujisawa et al.· International Journal of Cli...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
